Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Comment by 88STR8Ton Jan 11, 2017 3:48pm
144 Views
Post# 25695879

RE:RE:RE:RE:jan 10 presentation

RE:RE:RE:RE:jan 10 presentationDear wwmeinc... quote from Echelon report below: "Sernova Does Have Some Cell Pouch Clinical Data Already, But More Substantive Clinical Studies Are On The Horizon Sernova was previously conducting a three-year, twenty-patient Phase I/II first-in-human clinical trial in collaboration with the University of Alberta and Edmonton Protocol innovator AMJ Shapiro (a collaborator on the 2015 preclinical study published in Transplantation, as we described above), but the trial was never completed and is identified in the US NIHs clinical database as being terminated, with apparently three patients enrolled in the study at the time." So... you wanna call Doug Loe at Echelon and tell him he was wrong? or should I....LOL Maybe you want to go to Sernova's website and read this: https://www.sernova.com/press/?ID=166 ...where Shapiro presented data on 2 HUMAN patients... ...maybe a little more homework is in order on your part...I am not here o spew lies about the company... I like what they're doing...I watch this as I know people with diabetes...young people... as an investor I was here, but not for now...they would have to greatly improve their communication to shareholders... GOOD LUCK AND DON'T FORGET TO DO YOUR HOMEWORK.... and Sernova should have told their shareloders that they terminated that clinical trial.....enuff said!
Bullboard Posts